Bausch & Lomb Corp SEC Filings

Bausch & Lomb Corp EVP and CFO Sam Eldessouky reported an equity award tied to performance. He acquired 70,578 common shares underlying performance stock units that met performance conditions as of February 18, 2026, from a grant originally made on March 1, 2023.

The earned performance stock units will vest on March 1, 2026, generally contingent on his continued employment through that date. Following this non-cash grant/award acquisition, his directly owned common shares total 391,394.

Bausch + Lomb reports 2025 total revenue of $5,101 million, up from $4,791 million in 2024 and $4,146 million in 2023, reflecting steady growth across its global eye health portfolio.

Vision Care generated $2,923 million, or 57% of revenue, Pharmaceuticals $1,284 million (25%) and Surgical $894 million (18%). The company sells about 400 products in roughly 100 countries and employs about 13,000 people.

Bausch + Lomb remains a majority-owned subsidiary of Bausch Health Companies Inc., which held about 88% of common shares as of February 11, 2026, and BHC continues to evaluate a potential separation of the eye health business, with no assurance it will be completed.

Bausch + Lomb reported solid growth for 2025 but remained unprofitable. Fourth-quarter revenue reached $1.405 billion, up 10% year over year, with full-year revenue of $5.101 billion, up 6%. All three segments – Vision Care, Surgical and Pharmaceuticals – grew mid- to high-single digits for the year.

Despite this, the company posted a Q4 GAAP net loss of $58 million and a full-year net loss of $360 million. Profitability looked stronger on a non-GAAP basis: Q4 adjusted EBITDA rose to $326 million and full-year adjusted EBITDA was $858 million. Management guided 2026 revenue to $5.375–$5.475 billion with $1.0–$1.05 billion in adjusted EBITDA excluding acquired IPR&D, implying continued growth and margin focus.

Bausch & Lomb Corp director Steven H. Collis filed an initial insider ownership report indicating that he does not beneficially own any company securities. The Form 3 confirms his role as a director of Bausch & Lomb while stating in the remarks that no securities are beneficially owned. A power of attorney is on file, authorizing an attorney-in-fact to sign on his behalf.

Bausch & Lomb Corp director reports no share ownership

Bausch & Lomb Corp (BLCO) director Alfonso Eduardo filed an initial ownership report stating that no securities of the company are beneficially owned. This Form 3 confirms that, as of the reported date, he does not hold Bausch & Lomb common stock or derivative securities in either a direct or indirect capacity.

Bausch + Lomb Corporation amended its existing credit agreement by arranging a new $2,802,125,000 tranche of term loans maturing in 2031, called the Replacement Term Loans. The proceeds were used to refinance its outstanding term B loans due 2031 and term B loans due 2028, effectively extending the earlier 2028 maturity to 2031.

The Replacement Term Loans amortize at 1.00% per year, with the first installment due on June 30, 2026. The applicable margin is 3.75% per year for loans referencing term SOFR and 2.75% per year for loans referencing the alternate base rate, representing margin reductions of 0.50% and 0.25%, respectively, compared with the prior term loans.

Bausch + Lomb Corporation filed an amended current report to update board committee assignments for two recently appointed directors. The company had previously disclosed that Eduardo C. Alfonso, MD, and Steven H. Collis would join the board effective January 1, 2026.

The amendment states that, effective January 1, 2026, Dr. Alfonso will serve on the Science and Technology Committee and Mr. Collis will serve on the Talent and Compensation Committee. These changes clarify how the new directors will participate in the company’s governance structure.

Bausch + Lomb Corporation announced that it has appointed Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026. They are filling vacancies created by the departures of Brett Icahn and Gary Hu from the board in August 2025.

The board determined that both new directors are independent under New York Stock Exchange and Toronto Stock Exchange rules and the company’s corporate governance guidelines. They have not yet been appointed to any board committees, will receive compensation under the standard Non-Employee Directors Compensation Policy, and have entered into the company’s standard director indemnification agreements. The company states there are no special arrangements or related-party transactions involving either new director that require disclosure.

Bausch + Lomb Corporation is refinancing part of its debt by allocating a new $2,802,125,000 tranche of term B loans, called the Replacement Term Loans. The company plans to use the proceeds to refinance its existing term B loans due 2031 and its term B loans due 2028.

The Replacement Term Loans are expected to carry a margin of 3.75% per year for loans tied to term SOFR and 2.75% per year for loans tied to the alternate base rate, reducing the margin by 0.50% on the 2031 loans and 0.25% on the 2028 loans. The new loans will mature on January 15, 2031, matching the current 2031 maturity and extending the 2028 loans’ maturity to that date. The company expects the refinancing to close in the first quarter of 2026 but notes there is no assurance it will be completed on these terms or at all.